Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-01-11
2005-01-11
Nolan, Patrick J. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S178100, C530S388240, C530S389200, C530S391100
Reexamination Certificate
active
06841153
ABSTRACT:
Methods for the prevention of adhesion formation involve the administration of therapeutic formulations to a patient which include antibodies to TIMP-1 or TIMP-1 antisense oligonucleotides. The formulations can also include suitable carriers, such as a hyaluronic acid matrix, for optimal administration. The treatment procedure can be initiated and monitored by a diagnostic procedure which involves the detection of elevated levels of TIMP-1 in a patient.
REFERENCES:
patent: 5744442 (1998-04-01), Richards et al.
patent: 5843673 (1998-12-01), Sharpe-Timms
patent: 20010034327 (2001-10-01), Brunner et al.
patent: 20030096755 (2003-05-01), Brunner et al.
patent: 20030176332 (2003-09-01), Olmarker
Kahan BD. Immunosuppressive therapy. Curr Opin Immunol. 4(5):553-560, 1992.*
Ward PA, Mulligan MS. Blocking of adhesion molecules in vivo as anti-inflammatory therapy. Ther Immunol 1(3):165-171, 199.*
Menino, Jr. et al., Expression of Proteinases and Proteinase Inhibitors During Embryo-Uterine Contact in the Pig. Dev. Genetics 1997, vol. 21, pp. 68-74.
Stearns et al, Cytokine (IL-10-6) Induction of Tissue Inhibitor of Metalloproteinase 1 in Primary Human Prostate Tumor Cell Lines. Oncology Research. 1995, vol. 7, Nos. 3/4, pp. 173-181, especially p. 179, Figure 5.
Oh et al., Matrix metalloproteinase-9/Gelatinase B is Required for Process Outgrowth by Oligodendrocytes. J. of Neuroscience. Oct. 1, 1999, vol. 19, pp. 8464-8475.
Hsu et al., Colon carcinoma cells with inactive nm 23 show increased motility and response to motility factors. Carcinogenesis. 1995, vol. 16, No. 9, pp. 2259-2262.
Alexander, C.M. and Werb, Z. “Targeted Disruption of the Tissue Inhibitor of Metalloproteinases Gene Increases the Invasive Behavior of Primitive Mesenchymal Cells Derived from Embryonic Stern Cells in Vitro”J. Cell Biol., 1992, 118:727-739.
Chegini, N. et al., “Comparative Analysis of Matrix Metalloproteanase (MMP-1), Tissue Inhibitor of MMP (TIMP-1) and MMP-1/TIMP-1 Complex Expression in Intraperitoneal Environment and Their Relation to Adhesion Development”Fertility and Sterility, mailed to subscribers Sep. 1998, 70(No. 3, Suppl. 1):S26-S27, abstract.
Forough, R. et al., “Generating Antibodies Against Secreted Proteins Using Vascular Smooth Muscle Cells Transduced with Replication-Defective Retrovirus”BioTechniques, 1996, 20:694-701.
Khokha, R. et al., “Antisense RNA—Induced Reduction in Murine TIMP Levels Confers Oncogenicity on Swiss 3T3 Cells”Science, 1989, 243(4893):947-950.
Burns James
Chegini Nasser
Diamond Michael P.
Holmdahl Lena E.
Genzyme Corporation
Haddad Maher
Nolan Patrick J.
Saliwanchik Lloyd & Saliwanchik
University of Florida
LandOfFree
Prevention of adhesions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of adhesions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of adhesions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3428064